Analysis of mRNA and microRNA profiles in ischemic cardiomyopathy with LVAD support
- 1Department of Cardiology, University of Nebraska Medical Center, Omaha, NE 68198-2265 USA
- 2Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE USA
- 3Department of Surgery, University of Nebraska Medical Center, Omaha, NE USA
Abstract
Background: Cardiac remodeling after myocardial infarction is common, and recovery from end stage ischemic cardiomyopathy (ICM) with left ventricular assist device (LVAD) therapy remains rare. Our goal was to identify micro-RNAs (miRNAs) associated with ICM and to evaluate responses to LVAD therapy to better understand epigenetic mechanisms regulating differential gene expression (DGE).
Methods: RNAs were isolated from human myocardial tissues of ICM (n = 11) pre- and post-LVAD placement, along with non-failing (NF) controls (n = 6). Expressions were quantified by utilizing a targeted cardiac panel for mRNA and the nCounter Human v2 miRNA panel for miRNA. Ingenuity pathway analysis (IPA) was performed with DGE. Targeted gene expression profile was validated by performing mRNA-seq.
Results: Compared to NF controls, 33 in pre- and 32 genes in post-LVAD were differentially expressed. IPA of mRNA revealed that signals of inflammatory cytokines and blood pressure disorder were activated in pre-LVAD ICM, and norepinephrine and cells migration were triggered in post-LVAD ICM compared to NF controls. Inflammatory response and apoptosis of cardiomyocytes were inhibited in post compared to pre-LVAD. Relative to NF controls, 195 in pre- and 120 miRNAs in post-LVAD ICM were differentially expressed. IPA of miRNA showed that apoptosis and fibrosis of the heart were stimulated both in pre- and post-LVAD ICM. RNA-seq results validated the targeted gene expression.
Conclusions: In ICM, miRNA expression is linked to apoptosis and fibrosis pathways. These changes persist in post-LVAD therapy and contribute to ongoing changes in mRNA expression associated with Heart failure.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11033-026-13007-y.
Related
- Single-nucleus RNA sequencing in ischemic cardiomyopathy reveals common transcriptional profile underlying end-stage heart failure
- Identification of prognostic biomarkers for nasopharyngeal carcinoma through microRNA‑mRNA network analysis combined with screening of immune‑related genes
- Plasma exosomal microRNA profiles associated with agitation symptoms in schizophrenia
- An integrative multi-omics modeling framework for chemotherapy response prediction through microRNA–target regulatory signatures
- Mechanical Loading Reshapes Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicle microRNA Cargo Toward Predicted Immunomodulatory and EV Cargo-Trafficking Pathways: An In Vitro Mechanobiology Study
BibTeX
@article{dhar2026analysis,
title = {{Analysis of mRNA and microRNA profiles in ischemic cardiomyopathy with LVAD support}},
author = {Kajari Dhar and Hesham Basma and Fang Qiu and John Y. Um and Daniel R. Anderson and Brian D. Lowes},
journal = {Molecular Biology Reports},
year = {2026},
month = oct,
doi = {10.1007/s11033-026-13007-y},
url = {https://doi.org/10.1007/s11033-026-13007-y},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Analysis of mRNA and microRNA profiles in ischemic cardiomyopathy with LVAD support
AU - Kajari Dhar
AU - Hesham Basma
AU - Fang Qiu
AU - John Y. Um
AU - Daniel R. Anderson
AU - Brian D. Lowes
PY - 2026
DA - 2026/10/25
JO - Molecular Biology Reports
DO - 10.1007/s11033-026-13007-y
UR - https://doi.org/10.1007/s11033-026-13007-y
AB - Background: Cardiac remodeling after myocardial infarction is common, and recovery from end stage ischemic cardiomyopathy (ICM) with left ventricular assist device (LVAD) therapy remains rare. Our goal was to identify micro-RNAs (miRNAs) associated with ICM and to evaluate responses to LVAD therapy to better understand epigenetic mechanisms regulating differential gene expression (DGE). Methods: RNAs were isolated from human myocardial tissues of ICM (n = 11) pre- and post-LVAD placement, along with non-failing (NF) controls (n = 6). Expressions were quantified by utilizing a targeted cardiac panel for mRNA and the nCounter Human v2 miRNA panel for miRNA. Ingenuity pathway analysis (IPA) was performed with DGE. Targeted gene expression profile was validated by performing mRNA-seq. Results: Compared to NF controls, 33 in pre- and 32 genes in post-LVAD were differentially expressed. IPA of mRNA revealed that signals of inflammatory cytokines and blood pressure disorder were activated in pre-LVAD ICM, and norepinephrine and cells migration were triggered in post-LVAD ICM compared to NF controls. Inflammatory response and apoptosis of cardiomyocytes were inhibited in post compared to pre-LVAD. Relative to NF controls, 195 in pre- and 120 miRNAs in post-LVAD ICM were differentially expressed. IPA of miRNA showed that apoptosis and fibrosis of the heart were stimulated both in pre- and post-LVAD ICM. RNA-seq results validated the targeted gene expression. Conclusions: In ICM, miRNA expression is linked to apoptosis and fibrosis pathways. These changes persist in post-LVAD therapy and contribute to ongoing changes in mRNA expression associated with Heart failure. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11033-026-13007-y.
SN - 0301-4851
SN - 1573-4978
ER -